Challenges and Opportunities for Novel Therapeutic Strategies in Pediatric Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 June 2024 | Viewed by 479
Special Issue Editors
Interests: cancer immunotherapy; translational research; childhood cancer; sarcoma; bispecific antibody; T cell immunotherapy; leukemia; neuroblastoma; osteosarcoma
Interests: developmental tumors: neuroblastoma, Ewing sarcoma, Wilm's tumor, brain stem glioma; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The last decade has seen a revolution in our understanding of the molecular and genetic basis of pediatric cancers. With this advance, molecular and genetic characterization is being integrated into cancer diagnosis, revealing subgroups of pediatric cancers with both prognostic and therapeutic relevance. This enables risk-adoptive therapy, focusing intensive therapy on the most aggressive cancers while refining the treatment for low-risk diseases, resulting in a significant reduction in serious long-term complications.
Cancer immunotherapy changed the prognosis of high-risk malignancies. By targeting cell surface antigens, immunotherapeutic strategies, such as monoclonal antibody, antibody-drug conjugates, T cell engaging bispecific antibody (BsAb), and chimeric antigen receptor (CAR) T cells, shifted the treatment paradigm of high-risk neuroblastoma and relapsed/refractory leukemia and lymphoma in pediatric patients. However, immunotherapy has not lived up to its promise in most pediatric solid tumors. How to define which tumors are more likely to respond to immunotherapy and how to activate the immune system via either cell-based or antibody-based strategies remain major challenges.
This Special Issue will highlight the advances in our understanding of pediatric malignancies and in the development of treatments including small-molecular-targeted therapies, BsAb, CART, transplant, radioisotope or drug conjugates, radiotherapy, and photoimmunotherapy and address current challenges and future prospects for a more personalized therapy for pediatric cancer patients.
Dr. Jeong A Park
Dr. Jaume Mora
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody-drug conjugate
- bispecific antibody
- cancer predisposition
- CAR T cell
- immunotherapy
- leukemia
- monoclonal antibody
- neuroblastoma
- pediatric cancer
- photoimmunotherapy
- precision medicine
- sarcoma
- translational research
- tyrosine kinase inhibitor
